Barinthus Biotherapeutics (NASDAQ:BRNS) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Barinthus Biotherapeutics (NASDAQ:BRNS) announced its quarterly earnings data on Thursday. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.01), Zacks reports.

Barinthus Biotherapeutics Stock Performance

Shares of BRNS traded down $0.03 during midday trading on Friday, hitting $1.35. 1,840 shares of the stock traded hands, compared to its average volume of 21,198. Barinthus Biotherapeutics has a 1-year low of $1.21 and a 1-year high of $5.10. The business’s 50 day moving average price is $1.53 and its two-hundred day moving average price is $2.21. The firm has a market capitalization of $52.69 million, a PE ratio of -0.73 and a beta of -0.52.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Barinthus Biotherapeutics in a research report on Friday, June 7th. Barclays cut their target price on shares of Barinthus Biotherapeutics from $7.00 to $3.00 and set an “overweight” rating on the stock in a report on Thursday, June 13th. Finally, William Blair reaffirmed an “outperform” rating on shares of Barinthus Biotherapeutics in a report on Thursday, June 13th.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.